ENOS MedShop ENOS Labs

Educational resource · All compounds discussed are for laboratory research use only · Not for human or veterinary use

News digest

Trending peptides

Notable developments from public sources, newest first. Summaries are for educational reference and are not medical advice.

  1. TRIUMPH-2 detailed results published in The Lancet

    Eli Lilly reported detailed Phase 3 results for investigational triple agonist retatrutide in adults with obesity and type 2 diabetes, presented at EASD 2026.

    Source

  2. Triple-acting amylin + GIP/GLP-1 combinations enter the spotlight

    Lilly announced EASD 2026 presentations including Phase 2 data for eloraTZP, combining an amylin receptor agonist with tirzepatide — an investigational approach.

    Source

  3. Retatrutide succeeds in two more Phase 3 trials

    Topline TRIUMPH-2 and TRIUMPH-3 results were announced; the company stated plans to submit a Biologics License Application to the FDA.

    Source

  4. First pivotal obesity readout for a triple hormone receptor agonist

    Topline TRIUMPH-1 results for retatrutide were announced, a milestone for multi-receptor incretin research.

    Source

Sourcing peptides for your lab?

Browse research-grade peptides with documentation at ENOS Labs USA. For research use only.

Visit ENOS Labs